{"filing":{"accession_number":"0001493152-26-024707","cik":"0001873835","ticker":"IMMX","company_name":"Immix Biopharma, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/form8-k.htm"},"events":[{"id":9515,"run_id":8345,"accession_number":"0001493152-26-024707","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The filing discloses interim clinical trial results from the Phase 2 NEXICART-2 trial showing that all four MRD-negative relapsed/refractory AL Amyloidosis patients have converted to complete response (CR), with a 95% CR rate (19/20) across the first 20 patients and no relapses observed. While this is positive clinical progress for a biopharmaceutical company's lead candidate, it does not fit neatly into the standard event taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, M\u0026A activity, or executive change. The disclosure is material to investors assessing the company's pipeline and regulatory prospects, but the event is best classified as other_material given the clinical-trial-update nature of the announcement.","company_name":"Immix Biopharma, Inc.","ticker":"IMMX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":1172,"accession_number":"0001493152-26-024707","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses interim clinical trial results from the Phase 2 NEXICART-2 trial showing that all four MRD-negative relapsed/refractory AL Amyloidosis patients have converted to complete response (CR), with a 95% CR rate (19/20) across the first 20 patients and no relapses observed. While this is positive clinical progress for a biopharmaceutical company's lead candidate, it does not fit neatly into the standard event taxonomy—it is neither an earnings release (no financial results), nor a material impairment, litigation, M\u0026A activity, or executive change. The disclosure is material to investors assessing the company's pipeline and regulatory prospects, but the event is best classified as other_material given the clinical-trial-update nature of the announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:01:16.413309+00:00","company_name":"Immix Biopharma, Inc.","ticker":"IMMX","filing_date":"2026-05-21"}]}